ATM and hematologic disorder: Inhibited tumorigenesis and prolonged survival of the Atm-deficient mice in the haploidentical setting is in line with the finding that haploidentical HSCT is a valuable alternative for patients with hematological disorders lacking a HLA-matched unrelated donor (36, 37).